Latest Von Willebrand disease Stories
DEERFIELD, Ill., April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc.
PLAINSBORO, N.J., March 26, 2015 /PRNewswire/ -- Novo Nordisk today announced the company will launch Novoeight(®) (Antihemophilic Factor [Recombinant]) in the United States for people living
CSL Behring Pioneered Donations to WFH Program; Further Underscores Commitment to Providing Global Bleeding Disorders Community with Access to Treatment KING OF PRUSSIA, Pa., Feb.
DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
SAN FRANCISCO, December 7, 2014 /PRNewswire/ -- Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
PLAINSBORO, N.J., Dec.
FLINT, Mich., Nov. 4, 2014 /PRNewswire/ -- American Homecare Federation, a Diplomat company (NYSE: DPLO), is celebrating 25 years of business this year.
JNC is the Bleeding Disorders Community's Original Golf and Baseball Competition for Kids with Hemophilia and/or von Willebrand disease (VWD) and Their Families PHOENIX, Oct.